


# Stabilis



## Morphine sulfate



Noms commerciaux

Dimor F	Brésil
Duramorph	Etats Unis d'Amérique
Infumorph	Etats Unis d'Amérique
Miniject Morphine	Grande Bretagne
Morphine	Canada
Morphine sulfate	France
Lavoisier	



### Stabilité des solutions

































































































































		2 & 15 mg/ml	23°C-25°C		12			65
		2 & 15 mg/ml	4°C		12			65
		0,04 & 0,4 mg/ml	23°C		7			117
		0,04 & 0,4 mg/ml	4°C		7			117
		0,2 mg/ml	14-22°C		336			1341
		1 mg/ml	22°C		91			115
		1 mg/ml	4°C		91			115
		50 mg/ml	37°C		90			2305
		2 & 15 mg/ml	23°C-25°C		12			65
		2 & 15 mg/ml	4°C		12			65
		0,04 & 0,4 mg/ml	23°C		7			117
		0,04 & 0,4 mg/ml	4°C		7			117
		5 mg/ml	23°C		30			120
		1 & 10 mg/ml	32°C		16			932

		1 >> 25 mg/ml	25°C		14				116
		1 >> 25 mg/ml	37°C		3				116
		1 >> 25 mg/ml	5°C		30				116
		10 mg/ml	23°C		31				121
		10 mg/ml	4°C		31				121
		1,2 mg/ml	21°C		36				340
		10 mg/ml	23°C		31				121
		10 mg/ml	4°C		31				121
		10 mg/ml	23°C		30				120
		25 & 50 mg/ml	23°C		31				121
		25 & 50 mg/ml	4°C		31				121
		1 mg/ml	25°C		1095				2064
		50 mg/ml	23°C		60				1709
		50 mg/ml	37°C		48				1709
		1 mg/ml	25°C		100				4303
		0,1 mg/ml	25°C		91				4395
		0,2 mg/ml	25°C		91				4395
		1,0 mg/ml	25°C		91				4395
		1,76 mg/ml	20°C-25°C		14				1968
		2 mg/ml	25°C		42				122
		5 mg/ml	4°C		60				1709
		5 & 50 mg/ml	23°C		60				1709
		5 & 50 mg/ml	37°C		48				1709
		0,02 mg/ml	25°C		91				4395
		0,04 mg/ml	25°C		91				4395
		2 & 15 mg/ml	23°C-25°C		12				65
		2 & 15 mg/ml	31°C		12				65
		2 & 15 mg/ml	4°C		12				65
		2 & 10 mg/ml	22°C		40				1810
		2 & 10 mg/ml	4°C		40				1810
		2 & 3 mg/ml	25°C		60				2123
		2 & 3 mg/ml	4°C		60				2123



## Stabilité en mélange

		7,5 mg/ml	15°C-30°C		Esmolol hydrochloride : 5 mg/ml	8		8
		2,5 & 5 mg/ml	20°C-25°C		Midazolam hydrochloride : 2,5 mg/ml	14		1492
		0,1 & 1 mg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4		1603
		0,5 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		1 mg/ml	22°C		Metoclopramide hydrochloride : 0,5 mg/ml	42		1495
		0,5 & 1,5 mg/ml	23°C-25°C		Tacrolimus : 5 & 20 µg/ml	4		814
		1 & 1,5 mg/ml	37°C		Baclofen : 0,2 & 0,8 mg/ml	30		1467
		7,5 mg/ml	37°C		Baclofen : 1,5 mg/ml	30		1678
		15 mg/ml	37°C		Baclofen : 1 mg/ml	30		1678
		21 mg/ml	37°C		Baclofen : 0,2 mg/ml	30		1678
		1 mg/ml	4°C		Metoclopramide hydrochloride : 0,5 mg/ml	189		1495
		0,5 mg/ml	20°C-25°C		Labetalol hydrochloride : 1 mg/ml	4		199
		1 mg/ml	22°C		Metoclopramide hydrochloride : 0,5 mg/ml	14		1495
		0,5 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		0,25 & 1 mg/ml	23°C-25°C		Midazolam hydrochloride : 0,1 & 0,5 mg/ml	3		86
		0,5 mg/ml	25°C		Fluconazole : 1 mg/ml	24		257
		1 mg/ml	4°C		Metoclopramide hydrochloride : 0,5 mg/ml	35		1495
		7,7 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2196
		50 mg/ml	37°C		Clonidine hydrochloride : 2 mg/ml Bupivacaine hydrochloride : 25 mg/ml	90		1948
		50 mg/ml	4°C		Clonidine hydrochloride : 2 mg/ml Bupivacaine hydrochloride : 25 mg/ml	90		1948
		1 mg/ml	22°C		Metoclopramide hydrochloride : 0,5 mg/ml	42		1495
		1 mg/ml	22°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	31		6
		1 mg/ml	22°C		Naloxone hydrochloride : 0.004 mg/ml	72		3434
		1 mg/ml	22°C		Naloxone hydrochloride : 0,0125 mg/ml	72		3434
		1 mg/ml	22°C		Naloxone hydrochloride : 0,025 mg/ml	72		3434
		0,1 & 0,5 mg/ml	23°C-25°C		Bupivacaine hydrochloride : 0,62 & 1,25 mg/ml	72		220
		1 & 25 mg/ml	25°C		Ketamine hydrochloride : 1 & 25 mg/ml	6		2350
		1 mg/ml	32°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	7		6
		1 mg/ml	4°C		Metoclopramide hydrochloride : 0,5 mg/ml	189		1495

		1 mg/ml	4°C		Ondansetron hydrochloride : 0,1 & 1 mg/ml	31		6
		1 mg/ml	4°C		Naloxone hydrochloride : 0,025 mg/ml	30		3434
		1 mg/ml	4°C		Naloxone hydrochloride : 0,0125 mg/ml	30		3434
		1 mg/ml	4°C		Naloxone hydrochloride : 0,004 mg/ml	30		3434
		50 mg/ml	23°C		Clonidine hydrochloride : 4 mg/ml	60		1708
		50 mg/ml	23°C		Bupivacaine hydrochloride : 25 mg/ml	60		1707
		50 mg/ml	37°C		Clonidine hydrochloride : 4 mg/ml	48		1708
		50 mg/ml	37°C		Bupivacaine hydrochloride : 25 mg/ml	48		1707
		5,9 mg/ml	37°C		Levomepromazine : 0,74 mg/ml	4		3279
		50 mg/ml	4°C		Clonidine hydrochloride : 4 mg/ml	60		1708
		50 mg/ml	4°C		Bupivacaine hydrochloride : 25 mg/ml	60		1707
		0,8 mg/ml	2-8°C		Alfentanil hydrochloride : 55 µg/ml	180		2086
		0,8 mg/ml	22°C		Alfentanil hydrochloride : 55 µg/ml	180		2086
		5 mg/ml	23°C		Clonidine hydrochloride : 0,25 mg/ml	60		1708
		5 mg/ml	23°C		Bupivacaine hydrochloride : 2,5 mg/ml	60		1707
		2 >> 10 mg/ml	23°C		Ketamine hydrochloride : 2 mg/ml	91		2322
		2,67 mg/ml	23°C		Ondansetron hydrochloride : 1,33 mg/ml	24		815
		1 >> 25 mg/ml	25°C		Ketamine hydrochloride : 1 >> 25 mg/ml	6		2350
		0,02 mg/ml	30°C		Ropivacain hydrochloride : 1 & 2 mg/ml	30		1665
		0,1 mg/ml	30°C		Ropivacain hydrochloride : 2 mg/ml	30		1665
		5 mg/ml	37°C		Clonidine hydrochloride : 0,25 mg/ml	48		1708
		5 mg/ml	37°C		Bupivacaine hydrochloride : 2,5 mg/ml	48		1707
		5 mg/ml	4°C		Clonidine hydrochloride : 0,25 mg/ml	60		1708
		5 mg/ml	4°C		Bupivacaine hydrochloride : 2,5 mg/ml	60		1707
		2,67 mg/ml	4°C		Ondansetron hydrochloride : 1,33 mg/ml	24		815
		2 >> 10 mg/ml	5°C		Ketamine hydrochloride : 2 mg/ml	91		2322
		2 mg/ml	18-24°C		Ropivacain hydrochloride : 6 mg/ml Ziconotide acetate : 0,2 µg/ml	14		3998
		1 mg/ml	2-8°C		Clonidine hydrochloride : 0,001 mg/ml	5		4730
		1 mg/ml	2-8°C		Clonidine hydrochloride : 0,02 mg/ml	5		4730
		10 mg/ml	2-8°C		Clonidine hydrochloride : 0,02 mg/ml	5		4730
		3,5 mg/ml	2-8°C		Ropivacain hydrochloride : 7.5 mg/ml Ziconotide acetate : 1 µg/ml	3		3998
		0,5 >> 30 mg/ml	2-8°C		Ziconotide acetate : 0,2 >> 3 µg/ml	7		4496

		1,76 mg/ml	20°C-25°C		Droperidol : 0,2 mg/ml	14		1968
		1 mg/ml	22°C		Metoclopramide hydrochloride : 0,5 mg/ml	42		1495
		1 mg/ml	23-27°C		Clonidine hydrochloride : 0,02 mg/ml	5		4730
		1 mg/ml	23-27°C		Clonidine hydrochloride : 0,001 mg/ml	5		4730
		10 mg/ml	23-27°C		Clonidine hydrochloride : 0,02 mg/ml	5		4730
		1 mg/ml	4°C		Metoclopramide hydrochloride : 0,5 mg/ml	189		1495
		0,5 mg/ml	37°C		Ropivacain hydrochloride : 0,5 mg/ml Ziconotide acetate : 0,5 µg/ml	14		4669
		6 mg/ml	37°C		Ropivacain hydrochloride : 8,5 mg/ml Ziconotide acetate : 0,5 µg/ml	21		4669
		10 mg/ml	37°C		Clonidine hydrochloride : 0,02 mg/ml	28		4730
		1 mg/ml	37°C		Clonidine hydrochloride : 0,001 mg/ml	28		4730
		0,5 mg/ml	37°C		Ropivacain hydrochloride : 8,5 mg/ml Ziconotide acetate : 0,5 µg/ml	60		4669
		0,5 mg/ml	37°C		Ropivacain hydrochloride : 0,5 mg/ml Ziconotide acetate : 2 µg/ml	60		4669
		0,05 mg/ml	23°C		Bupivacaine hydrochloride : 1 mg/ml	28		1276
		35 mg/ml	37°C		Ziconotide acetate : 25 µg/ml	8		2251
		20 mg/ml	37°C		Ziconotide acetate : 25 µg/ml	19		2298
		10 mg/ml	37°C		Ziconotide acetate : 25 µg/ml	34		2298
		50 mg/ml	37°C		Bupivacaine hydrochloride : 24 mg/ml Clonidine hydrochloride : 2 mg/ml	90		2305
		0,05 mg/ml	4°C		Bupivacaine hydrochloride : 1 mg/ml	28		1276
		20 mg/ml	5°C		Ziconotide acetate : 25 µg/ml	28		2298
		10 mg/ml	5°C		Ziconotide acetate : 25 µg/ml	60		2298
		20 mg/ml	37°C		Clonidine hydrochloride : 0,05 mg/ml	90		1869
		2 mg/ml	37°C		Clonidine hydrochloride : 1,84 mg/ml	90		1869
























































### Facteur influençant la stabilité

				119
				1415
	PH >7			3531



## Compatibilités

			
			3595
			3531
			336
			62
			2086
			307
			240
			3
			405
			3531
			1611
			1611
			295
			3531
			3824
			921
			405
			406
			253
			1982
			1964
			62
			402
			1974

		Morphine sulfate : 1 mg/ml Azithromycine : 2 mg/ml		1800
		Morphine sulfate : 1 mg/ml Aztreonam : 20 mg/ml		62
		Morphine sulfate : 1 mg/ml Aztreonam : 40 mg/ml		99
		Morphine sulfate : 7.5 >> 21 mg/ml Baclofen : 0.2 >> 1.5 mg/ml		1678
		Morphine sulfate : 1 & 1.5 mg/ml Baclofen : 0.2 & 0.8 mg/ml		1467
		Morphine sulfate : 1 & 10 mg/ml Baclofen : 0.08 & 1.6 mg/ml		4051
		Morphine sulfate : 1 mg/ml Bivalirudin : 5 mg/ml		1713
		Morphine sulfate : 10 mg/ml Bivalirudin : 5 mg/ml		1944
		Morphine sulfate : 1 mg/ml Bumetanide : 0.25 mg/ml		62
		Morphine sulfate : 129 mg/ml Bupivacaine hydrochloride : 7,5 mg/ml		221
		Morphine sulfate : 25 mg/ml Bupivacaine hydrochloride : 20 mg/ml		3131
		Morphine sulfate : 0,05 mg/ml Bupivacaine hydrochloride : 1 mg/ml		1276
		Morphine sulfate : 0,1 & 0,5 mg/ml Bupivacaine hydrochloride : 0,625 & 1,250 mg/ml		220
		Morphine sulfate : 50 mg/ml Caffeine : 10 mg/ml		3964
		Morphine sulfate Calcium gluconate		3644
		Morphine sulfate : 2 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Morphine sulfate : 15 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Morphine sulfate : 1 mg/ml Cefalotin sodium : 20 mg/ml		405
		Morphine sulfate : 1 mg/ml Cefamandole nafate : 40 mg/ml		406
		Morphine sulfate : 1 mg/ml Cefamandole nafate : 20 mg/ml		405
		Morphine sulfate : 1 mg/ml Cefazolin sodium : 20 mg/ml		405
		Morphine sulfate : 100 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Morphine sulfate : 1 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Morphine sulfate : 1 mg/ml Cefoperazone sodium : 20 mg/ml		405
		Morphine sulfate : 1 mg/ml Ceforanide : 20 mg/ml		405
		Morphine sulfate : 1 mg/ml Cefotaxime sodium : 20 mg/ml		405

	Morphine sulfate : 1 mg/ml Cefoxitin sodium : 20 mg/ml		405	
	Morphine sulfate : 1 mg/ml Cefoxitin sodium : 40 mg/ml		406	
	Morphine sulfate : 15 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249	
	Morphine sulfate : 15 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249	
	Morphine sulfate : 1 mg/ml Ceftazidime : 20 & 40 mg/ml		62	
	Morphine sulfate : 1 mg/ml Ceftizoxime sodium : 20 mg/ml		405	
		Morphine sulfate : 15 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Morphine sulfate Ceftobiprole medocaril sodium		4650
	Morphine sulfate : 5 mg/ml		3948	
	Morphine sulfate : 1 mg/ml		1415	
		Morphine sulfate : 15 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Morphine sulfate : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828	
	Morphine sulfate : 1 mg/ml Ceftriaxone disodium : 20 & 40 mg/ml		62	
	Morphine sulfate : 1 mg/ml Cefuroxime sodium : 30 mg/ml		405	
		Morphine sulfate : 50 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Morphine sulfate : 1 mg/ml Co-trimoxazole : 4/0.8 mg/ml		405	
		Morphine sulfate : 15 mg/ml		1415
	Morphine sulfate : 1 mg/ml Chloramphenicol sodium succinate : 20 mg/ml		405	
	Morphine sulfate : 10 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438	
	Morphine sulfate : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299	
		Morphine sulfate Cisplatin		3578
	Morphine sulfate : 1 mg/ml Cladribine : 0.5 mg/ml		1496	
	Morphine sulfate : 1 mg/ml Cladribine : 0.015 mg/ml		1496	
	Morphine sulfate : 1 mg/ml Clindamycin phosphate : 12 mg/ml		405	
	Morphine sulfate : 50 mg/ml Clonidine hydrochloride : 4 mg/ml		1708	
	Morphine sulfate : 5 mg/ml Clonidine hydrochloride : 0.25 mg/ml		1708	
	Morphine sulfate : 2 & 20 mg/ml Clonidine hydrochloride : 0,05 & 1,84 mg/ml		1869	



	Morphine sulfate : 1 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		1974
	Morphine sulfate : 1 mg/ml Dexamethasone sodium phosphate : 0.2 mg/ml		62
	Morphine sulfate : 1 mg/ml Digoxin : 250 µg/ml		62
	Morphine sulfate : 1 mg/ml		316
	Morphine sulfate : 1 mg/ml Diazepam : 0.5 mg/ml		1974
	Morphine sulfate : 0.4 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Morphine sulfate : 15 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
	Morphine sulfate : 0.1 mg/ml		340
	Morphine sulfate : 1 mg/ml		62
	Morphine sulfate : 5 mg/ml		3948
	Morphine sulfate : 1 mg/ml		301
	Morphine sulfate : 50 mg/ml	RL	4603
	Morphine sulfate : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
	Morphine sulfate : 1 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		1974
	Morphine sulfate : 2 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
	Morphine sulfate : 10 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
	Morphine sulfate : 1 mg/ml Docetaxel : 0.9 mg/ml		1754
	Morphine sulfate : 1 mg/ml Dopamine hydrochloride : 1.6 mg/ml		62
	Morphine sulfate : 2 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Morphine sulfate Doxorubicin hydrochloride		3531
	Morphine sulfate : 1 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Morphine sulfate : 1 mg/ml Doxycycline hyclate : 1 mg/ml		405
	Morphine sulfate Doxycycline hyclate		3531
	Morphine sulfate : 0.2 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Morphine sulfate : 2 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Morphine sulfate Eptifibatide		3934
	Morphine sulfate Eravacycline		3531

	Morphine sulfate : 1 mg/ml Eravacycline : 0,6 mg/ml		4434
	Morphine sulfate : 1 mg/ml Erythromycin lactobionate : 5 mg/ml		405
	Morphine sulfate : 7,5 mg/ml Esmolol hydrochloride : 5 mg/ml		8
	Morphine sulfate : 7,5 mg/ml Esmolol hydrochloride : 5 mg/ml		8
	Morphine sulfate : 10 mg/ml Etomidate : 2 mg/ml		319
	Morphine sulfate : 1 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Morphine sulfate : 1 mg/ml Famotidine : 0.2 mg/ml		62
	Morphine sulfate : 0.2 mg/ml Famotidine : 0.2 mg/ml		398
	Morphine sulfate : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Morphine sulfate : 2 mg/ml Fentanyl citrate : 50 µg/ml		314
	Morphine sulfate : 1 mg/ml Filgrastim : 30 µg/ml		244
	Morphine sulfate : 1 mg/ml Fluconazole : 1 mg/ml		62
	Morphine sulfate : 25 mg/ml Fluconazole : 2 mg/ml		496
	Morphine sulfate : 1 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Morphine sulfate Fluorouracil		3531
	Morphine sulfate Fluorouracil		3474
	Morphine sulfate : 1 mg/ml Fluorouracil : 1 & 16 mg/ml		513
	Morphine sulfate : 1 mg/ml Foscarnet sodium : 24 mg/ml		73
	Morphine sulfate : 15 mg/ml Foscarnet sodium : 24 mg/ml		64
	Morphine sulfate : 1 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Morphine sulfate : 5 mg/ml Foscarnet sodium : 24 mg/ml		64
	Morphine sulfate : 1 mg/ml Fosfomycin : 30 mg/ml		4055
	Morphine sulfate : 1 mg/ml Furosemide : 1 mg/ml		1232
	Morphine sulfate : 1 mg/ml Furosemide : 0.8 >> 10 mg/ml		62
	Morphine sulfate Furosemide		3531
	Morphine sulfate : 2 mg/ml Furosemide : 10 mg/ml		314

		Morphine sulfate : 10 mg/ml Gallium nitrate : 1 mg/ml		91
		Morphine sulfate : 1 mg/ml Gallium nitrate : 1 mg/ml		91
		Morphine sulfate : 1 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Morphine sulfate : 1 mg/ml Gentamicin sulfate : 0.8 mg/ml		405
		Morphine sulfate : 1 mg/ml Gentamicin sulfate : 1.2 & 2 mg/ml		406
		Morphine sulfate Glycopyrronium bromide		3599
		Morphine sulfate : 1 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Morphine sulfate : 1 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Morphine sulfate : 2,5 & 5 mg/ml Haloperidol lactate : 2.5 mg/ml		1492
		Morphine sulfate : 1 mg/ml Haloperidol lactate : 0.2 mg/ml		1974
		Morphine sulfate : 15 mg/ml Heparin sodium : 1 UI/ml		1228
		Morphine sulfate : 1 >> 10 mg/ml Heparin sodium : 100 & 200 UI/ml		341
		Morphine sulfate : 10 mg/ml Heparin sodium : 100 & 200 UI/ml		341
		Morphine sulfate : 1 >> 5 mg/ml Heparin sodium : 100 & 200 UI/ml		341
		Morphine sulfate : 1 mg/ml Heparin sodium : 60 UI/ml		406
		Morphine sulfate Heparin sodium		3531
		Morphine sulfate : 2 mg/ml Heparin sodium : 100 UI/ml		314
		Morphine sulfate : 15 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Morphine sulfate : 1 mg/ml Hetastarch : 60 mg/ml		1721
		Morphine sulfate Hyaluronidase		3184
		Morphine sulfate : 15 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Morphine sulfate : 15 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Morphine sulfate : 2 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Morphine sulfate : 1 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml		1974
		Morphine sulfate : 0.5 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Morphine sulfate : 50 mg/ml Ibuprofen lysinate : 10 mg/ml		4419

	Morphine sulfate : 1 mg/ml Insulin : 0.2 UI/ml		406
	Morphine sulfate : 1 mg/ml Insulin : 1 UI/ml		295
	Morphine sulfate : 5 mg/ml Insulin : 0.2 UI/ml		129
	Morphine sulfate : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml	 	3829
	Morphine sulfate : 1 mg/ml Kanamycin sulfate : 2.5 mg/ml		405
	Morphine sulfate : 2 >> 10 mg/ml Ketamine hydrochloride : 2 mg/ml		2322
			3593
	Morphine sulfate : 1 mg/ml Ketorolac tromethamine : 1 mg/ml		1974
	Morphine sulfate : 0.5 mg/ml Labetalol hydrochloride : 1 mg/ml		199
	Morphine sulfate : 2 mg/ml Labetalol hydrochloride : 2 mg/ml		314
	Morphine sulfate : 1 mg/ml Labetalol hydrochloride : 1 mg/ml		386
	Morphine sulfate : 1 mg/ml Labetalol hydrochloride : 5 mg/ml		62
	Morphine sulfate : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Morphine sulfate : 0,05 mg/ml Levobupivacaine hydrochloride		3507
	Morphine sulfate : 4 mg/ml Levofloxacin : 5 mg/ml		1072
	Morphine sulfate Levomepromazine		3279
	Morphine sulfate : 50 mg/ml Levosimendan : 2,5 mg/ml		4389
	Morphine sulfate : 1 mg/ml Lidocaine hydrochloride : 1 mg/ml		62
	Morphine sulfate : 1 mg/ml Linezolid : 2 mg/ml		1925
	Morphine sulfate : 2 mg/ml Lorazepam : 0.5 mg/ml		314
	Morphine sulfate : 1 mg/ml Lorazepam : 0.1 mg/ml		1974
	Morphine sulfate : 1 mg/ml Magnesium sulfate : 16,67 >> 100 mg/ml		517
	Morphine sulfate : 2 mg/ml Magnesium sulfate : 2 >> 8 mg/ml		218
	Morphine sulfate : 1 mg/ml Melphalan : 0.1 mg/ml		169
	Morphine sulfate : 50 mg/ml Meropenem : 50 mg/ml		4319
	Morphine sulfate : 1 mg/ml Meropenem : 1 >> 50 mg/ml		266

		Morphine sulfate Methohexital sodium		3531
		Morphine sulfate : 1 mg/ml Methylprednisolone sodium succinate : 2.5 mg/ml		62
		Morphine sulfate : 1 mg/ml Metoclopramide hydrochloride : 5 mg/ml		1974
		Morphine sulfate : 1 mg/ml Metoclopramide hydrochloride : 0.2 mg/ml		62
		Morphine sulfate : 1 mg/ml Metoclopramide hydrochloride : 0.5 mg/ml		1495
		Morphine sulfate : 1 mg/ml Metoprolol tartrate : 1 mg/ml		62
		Morphine sulfate : 1 mg/ml Metronidazole : 5 mg/ml		405
		Morphine sulfate : 15 mg/ml Micafungin : 1.5 mg/ml		2108
		Morphine sulfate : 1 mg/ml Midazolam hydrochloride : 0.2 mg/ml		1974
		Morphine sulfate : 2 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Morphine sulfate : 5 mg/ml Midazolam hydrochloride : 2.5 mg/ml		404
		Morphine sulfate : 0,25 & 1 mg/ml Midazolam hydrochloride : 0,1 & 0,5 mg/ml		86
		Morphine sulfate : 2,5 & 5 mg/ml Midazolam hydrochloride : 2,5 mg/ml		1492
		Morphine sulfate : 1 mg/ml Midazolam hydrochloride : 1 mg/ml		295
		Morphine sulfate : 2 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Morphine sulfate : 2 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Morphine sulfate : 1 mg/ml Minocycline hydrochloride : 0.2 mg/ml		405
		Morphine sulfate Minocycline hydrochloride		3531
		Morphine sulfate Morphine tartrate		519
		Morphine sulfate : 1 mg/ml Moxalactam : 20 mg/ml		405
		Morphine sulfate : 1 mg/ml Nafcillin sodium : 20 & 30 mg/ml		406
		Morphine sulfate : 1 mg/ml Nafcillin sodium : 20 mg/ml		405
		Morphine sulfate : 1 mg/ml Naloxone hydrochloride : 0,004 >> 0,025 mg/ml		3434
		Morphine sulfate : 2 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Morphine sulfate : 0.2 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Morphine sulfate : 2 mg/ml Nitroglycerin : 0.4 mg/ml		314

	Morphine sulfate : 1 mg/ml Nitroprusside sodium : 0.2 mg/ml		295
	Morphine sulfate : 1 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		295
	Morphine sulfate : 2 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	Morphine sulfate : 2.67 mg/ml Ondansetron hydrochloride : 1.33 mg/ml		815
	Morphine sulfate : 1 mg/ml Ondansetron hydrochloride : 0,1 & 1 mg/ml		6
	Morphine sulfate : 1 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Morphine sulfate : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
	Morphine sulfate : 1 mg/ml Oxacillin sodium : 20 mg/ml		405
	Morphine sulfate : 15 mg/ml Oxaliplatin : 0,5 mg/ml		1662
	Morphine sulfate Oxytetracycline hydrochloride		3531
	Morphine sulfate : 1 mg/ml Oxytocin : 12 UI/ml		406
	Morphine sulfate : 1 mg/ml Paclitaxel : 1.2 mg/ml		248
	Morphine sulfate : 15 mg/ml Palonosetron hydrochloride : 50 µg/ml		2196
	Morphine sulfate : 1 mg/ml Pancuronium bromide : 0.05 mg/ml		402
	Morphine sulfate : 10 mg/ml Paracetamol : 10 mg/ml		4742
	Morphine sulfate : 15 mg/ml Paracetamol : 10 mg/ml		3571
	Morphine sulfate Parecoxib sodium		3504
	Morphine sulfate : 15 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Morphine sulfate : 1 mg/ml Penicillin G potassium : 0.1 MUI/ml		405
	Morphine sulfate Pentobarbital sodium		3531
	Morphine sulfate : 0,02 mg/ml Pentoxifyllin : 5 mg/ml		4543
	Morphine sulfate : 0,08 & 0,2 mg/ml Pentoxifyllin : 5 mg/ml		4538
	Morphine sulfate Pethidine hydrochloride		3531
	Morphine sulfate Pethidine hydrochloride		3525
	Morphine sulfate : 1 mg/ml Phenobarbital sodium : 2 mg/ml		1974
	Morphine sulfate Phenobarbital sodium		3531

		Morphine sulfate : 1 mg/ml Phenytoin sodium : 2 mg/ml		1974
		Morphine sulfate Phenytoin sodium		3531
		Morphine sulfate : 1 mg/ml Piperacillin sodium : 60 mg/ml		405
		Morphine sulfate : 1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Morphine sulfate : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Morphine sulfate Posaconazole		4380
		Morphine sulfate Prochlorperazine edysilate		1079
		Morphine sulfate : 10 mg/ml Prochlorperazine edysilate : 5 mg/ml		1020
		Morphine sulfate Promethazine hydrochloride		3531
		Morphine sulfate : 10 mg/ml Propofol : 2 mg/ml		319
		Morphine sulfate : 1 mg/ml Propofol : 10 mg/ml		300
		Morphine sulfate : 10 mg/ml Propofol		660
		Morphine sulfate : 1 mg/ml Propranolol hydrochloride : 1 mg/ml		62
		Morphine sulfate : 10 mg/ml Ranitidine hydrochloride : 25 mg/ml		58
		Morphine sulfate : 2 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Morphine sulfate : 1 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		406
		Morphine sulfate : 1 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Morphine sulfate : 0.02 & 0.1 mg/ml Ropivacain hydrochloride : 1 & 2 mg/ml		1665
		Morphine sulfate : 0,02 >> 0,1 mg/ml Ropivacain hydrochloride : 1 - 2 mg/ml		1516
		Morphine sulfate : 1 mg/ml Sargramostim : 10 µg/ml		335
		Morphine sulfate : 1 mg/ml Scopolamine hydrobromide : 0.05 mg/ml		1974
		Morphine sulfate : 1 mg/ml Scopolamine hydrobromide : 0.05 mg/ml		1974
		Morphine sulfate : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Morphine sulfate : 0,5 & 1,5 mg/ml Tacrolimus : 5 & 20 µg/ml		814
		Morphine sulfate : 1 mg/ml Teniposide : 0.1 mg/ml		905
		Morphine sulfate Thiopental sodium		3675

		Morphine sulfate : 10 mg/ml Thiopental sodium : 25 mg/ml		319
		Morphine sulfate Thiopental sodium		3531
		Morphine sulfate : 2 mg/ml Thiopental sodium : 25 mg/ml		314
		Morphine sulfate : 1 mg/ml Thiotepa : 1 mg/ml		249
		Morphine sulfate : 1 mg/ml Ticarcillin / clavulanic acid : 31 mg/ml		406
		Morphine sulfate Tigecycline		3531
		Morphine sulfate Tirofiban		1512
		Morphine sulfate : 0,1 & 1 mg/ml Tirofiban : 50 µg/ml		1603
		Morphine sulfate : 1 mg/ml Tobramycin sulfate : 0.8 mg/ml		405
		Morphine sulfate : 1 mg/ml Tobramycin sulfate : 1.6 >> 2.4 mg/ml		406
		Morphine sulfate : 1 mg/ml Vancomycin hydrochloride : 5 mg/ml		405
		Morphine sulfate : 2 mg/ml Vecuronium bromide : 1 mg/ml		314
		Morphine sulfate : 1 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Morphine sulfate : 0.03 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Morphine sulfate : 1 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Morphine sulfate : 2 mg/ml Warfarin sodium : 2 mg/ml		315
		Morphine sulfate : 1 mg/ml Zidovudine : 4 mg/ml		337



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.



6	Revue	Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm 1994 ; 51: 2138-2142.
8	Revue	Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 368-371.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
64	Revue	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
65	Revue	Duafala ME, Kleinberg ML, Nacov C, Flora KP, Hines J, Davis K, McDaniel A, Scott D. Stability of morphine sulfate in infusion devices and containers for intravenous administration. Am J Hosp Pharm 1990 ; 47: 143-146.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
86	Revue	Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA. Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration. Am J Hosp Pharm 1994 ; 51: 2812-2815.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

115	Revue	Nahata MC, Morosco RS, Hipple TF. Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures. Am J Hosp Pharm 1992 ; 49: 2785-2786.
116	Revue	Stiles ML, Tu YH, Allen LV Jr. Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration. Am J Hosp Pharm 1989 ; 46: 1404-1407.
117	Revue	Vecchio M, Walker SE, Iazzetta J, Hardy BG. The stability of morphine intravenous infusion solutions. Can J Hosp Pharm 1988 ; 41: 5-9.
119	Revue	Strong ML, Schaaf LJ, Pankaskie MC, Robinson DH. Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices. J Clin Pharm Ther 1994 ; 19: 361-369.
120	Revue	Walker SE, Coons C, Matte D, DeAngelis C, Iazzetta J, Kolos C, Birkhans B. Hydromorphone and morphine stability in portable infusion pump cassettes and minibags. Can J Hosp Pharm 1988 ; 41: 177-182.
121	Revue	Walker SE, Iazzetta J, Lau DWC. Stability of sulfite free high potency morphine sulfate solutions in portable infusion pump cassettes. Can J Hosp Pharm 1989 ; 42: 195-200.
122	Revue	Grassby PF, Hutchings L. Factors affecting the physical and chemical stability of morphine sulphate solutions stored in syringes. Int J Pharm Pract 1993 ; 2: 39-43.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
199	Revue	Hassan E, Leslie J, Martir-Herrero ML. Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 2143-2145.
218	Revue	Vogt C, Ruggaber S. Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection. Am J Hosp Pharm 1993 ; 50: 2311.
220	Revue	Johnson CE, Christen C, Perez MM, Ma M. Compatibility of bupivacaine hydrochloride and morphine sulfate. Am J Health-Syst Pharm 1997 ; 54: 61-64.
221	Revue	Neels JT. Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate. Am J Hosp Pharm 1992 ; 49: 2149.
240	Revue	Lam XM, Ward CA, de C du M'e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.

248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
257	Revue	Hunt-Fugate AK, Hennessey CK, Kazarian CM. Stability of fluconazole in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1186-1187.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.

335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
340	Revue	Macias JM, Martin WJ, Lloyd CW. Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation. Am J Hosp Pharm 1985 ; 42: 1087-1094.
341	Revue	Baker DE, Yost GS, Craig VL, Campbell RK. Compatibility of heparin sodium and morphine sulfate. Am J Hosp Pharm 1985 ; 42: 1352-1355.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
513	Revue	Xu QA, Trissel LA, Martinez JF. Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Ann Pharmacotherapy 1996 ; 30: 756-761.
517	Revue	Letourneau M. Visual compatibility of magnesium sulfate with narcotic analgesics. Am J Hosp Pharm 1992 ; 49: 838-839.
519	Revue	Poggi GL. Compatibility of morphine tartrate admixtures in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 316.

660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
814	Revue	Johnson CE, VandenBussche HL, Chio CC, Jacobson PA. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. Am J Health-Syst Pharm 1999 ; 56: 164-169.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
932	Revue	Hor MMS, Chan SY, Yow KL, Lim LY, Chan E, Ho PC. Stability of morphine sulphate in saline under simulated patient administration conditions. J Clin Pharm Ther 1997 ; 22: 405-410.
1020	Revue	Zuber DEL. Compatibility of morphine sulfate injection and prochlorperazine injection. Am J Hosp Pharm 1987 ; 44: 67.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1079	Revue	Stevenson JG, Patriarca C. Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes. Am J Hosp Pharm 1985 ; 42: 2651.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1276	Revue	Shiffman E, Walker SE, Yoon T, Yeung M. Stability and compatibility of morphine with bupivacaine. Can J Hosp Pharm 1998 ; 51: 110-116.

1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1341	Revue	Deeks T, Davis S, Nash S. Stability of an intrathecal morphine injection formulation. Pharm J 1983 ; 230: 495-497.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1467	Revue	Sitaram BR, Tsui M, Rawicki HB, Lam S, Courage P, Sitaram M, Chapman CB. Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump. Int J Pharm 1995 ; 118: 181-189.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1492	Revue	LeBelle MJ, Savard C, Gagnon A. Compatibility of morphine and midazolam or haloperidol in parenteral admixtures. Can J Hosp Pharm 1995 ; 48: 155-160.
1495	Revue	Nixon AR, O'Hare MCB, Chisakuta AM. The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations. Pharm J 1995 ; 254: 153-155.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1516	Laboratoire	Ropivacaine (Naropeine®) - Summary of Product Characteristics Mercury Pharmaceuticals Limited 2012
1603	Revue	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1665	Revue	Öster Svedberg K, McKenzie J, Larrivee-Elkins C. Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine. J Clin Pharm Ther 2002 ; 21: 39-45.

1678	Revue	Sitaram BR, Tsui M, Rawicki HB, Lam S, Sitaram M. Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine. Int J Pharm 1997 ; 153: 13-24.
1707	Revue	Trissel LA, Xu QA, Pham L. Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes. Int J Pharm Compound 2002 ; 6: 70-73.
1708	Revue	Xu QA, Trissel LA, Pham L. Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes. Int J Pharm Compound 2002 ; 6: 66-69.
1709	Revue	Trissel LA, Xu QA. Physical and chemical stability of morphine sulfate 5 mg/ml and 50 mg/ml packaged in plastic syringes. Int J Pharm Compound 2002 ; 6: 62-65.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1810	Revue	Lee G, Sabra K, Doyle N, Malley GO. Stability of morphine sulphate in P.C.A.s. EJHP 2003 ; 1:1-3.
1869	Revue	Hildebrand KR, Elsberry DD, Hassenbusch SJ. Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system. J Pain Symptom Manage 2003 ; 25, 5: 464-471.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Revue	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1948	Revue	Classen AM, Wimbish GH, Kupiec TC. Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage 2004 ; 28, 6: 603-611.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.

1968	Revue	Williams OA, Middleton M, Henderson P, Reilly CS. Stability of morphine and droperidol separately and combined, for use as an infusion. Hosp Pharm Pract 1992 ; 2, 9: 597-600.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2064	Revue	Nguyen-Xuan Tho, Griffiths W, Kern C, Van Gessel E, Bonnabry P. Stability of morphine sulfate in polypropylene infusion bags for use in patient-controlled analgesia pumps for postoperative pain management. Int J Pharm Compound 2006 ; 10: 69-73.
2086	Revue	Sharley NA, Burgess NG. Stability and compatibility of alfentanil hydrochloride and morphine sulfate in polypropylene syringes. J Pharm Pract and Res 2003 ; 33: 279-281.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2123	Revue	Lee G, Sabra K. Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets. EJHP Science 2006 ; 12, 4: 76-80.
2196	Revue	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2251	Revue	Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005 ; 8, 4: 257-263.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2298	Revue	Shields D.E, Aclan J, Szatkowski A. Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration. Int J Pharm Compound 2008 ; 12, 6: 553-557.
2305	Revue	Bianchi F, Ginggen A, Tardy Y. Stability and compatibility of drug mixtures in an implantable infusion system. Anaesthesia 2008 63, 9: 972-978.
2322	Revue	Donnelly R.F. Physical Compatibility and Chemical Stability of Ketamine–Morphine Mixtures in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 1



2350	Revue	Roy J.J, Hildgen P. Stability of morphine-ketamine in 0.9% sodium chloride injection packaged in syringes, plastic bags and MEDICATION CASSETTE Reservoirs. Int J Pharm Compound 2000 ; 4, 3: 225-228.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3131	Revue	Donnelly RF, Wong K, Spencer J. Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl. Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3249	Revue	<del>Can Pharm J</del> Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3279	Revue	Al-Tannak N.F, Cable C.G, McArthur D.A, Watson D.G A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care. J Clin Pharm Ther 2012 ; 37, 1: 71-73.
3434	Revue	Kistner C, Ensom M.H.H, Decarie D, Lauder G, Carr R.R. Compatibility and Stability of Morphine Sulphate and Naloxone Hydrochloride in 0.9% Sodium Chloride for Injection. Can J Hosp Pharm 2013 ; 66, 3 : 167-170.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3504	Laboratoire	Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012
3507	Laboratoire	Chirocaine - Summary of Product Characteristics AbbVie 2013
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3593	Laboratoire	Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics Beacon Pharmaceuticals 2011
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3675	Laboratoire	Thiopental sodium - Summary of Product Characteristics Archimedes Pharma UK Ltd 2015


3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3934	Laboratoire	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P. Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3998	Revue	Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoirion D, Devys C. Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia. Int J Pharm Compound 2017 ; 21:4 :347-351
4051	Revue	Robert J, Sorrieul J, Kieffer H, Folliard C, Gibory V, Dupoirion D, Devys C. Stability study of morphine and baclofen solution in polypropylene syringes. Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4:173-180
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4303	Revue	Anderson C, MacKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385.
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4395	Poster	Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E. Stability of Morphine Solutions of 20, 40, 100 , 200 and 1,000 µg/mL in Syringes Following Dilution with 0.9% Sodium Chloride or D5W at Room Temperature (25°C). Sunnybrook Health Sciences Centre 2020
4419	Revue	Holt R.J, Siebert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.

4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4496	Revue	Sorrieul J, Robert J, Dupoirion D, Devys, C. Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes. Neuromodulation 2020 ; 24, 7: 1145-1156.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4669	Revue	Robert J, Sorrieul J, Dupoirion D, Jubier-Hamon S, Bienfait F, Visbecq A, Devys C. Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration. Neuromodulation 2021 : 1-16.
4730	Revue	Sorrieul J, Robert J, Vincent L, Andre M, Bourcier B, Bienfait F, Jubier Hamon S, Dupoirion D, Devys C. Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures. Neuromodulation 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

# Stabilis



## Morphine sulfate



### Stabilité des préparations

20 mg @=? Martindale Pharmaceuticals		Instillagel® >> 20 ml	25°C		22			2828
315 mg @=? (Arum Pharmaceutical)		Instillagel® >> 25 mL	25°C		28			2914
20 mg @=? Martindale Pharmaceuticals		Instillagel® >> 20 ml	37°C		210			2828
20 mg @=? Martindale Pharmaceuticals		Instillagel® >> 20 ml	4°C		22			2828
315 mg @=? (Arum Pharmaceutical)		Instillagel® >> 25 mL	4°C		28			2914




### Bibliographie

	Type	Source
2828	Revue	Abdelmageed R, Labyad N, Watson DG, Pournamdari M, Cable CG, Stanley E. Evaluation of the stability of morphine sulphate in combination with Instillagel®. J Clin Pharm Ther 2008 ; 33, 3: 263-271.
2914	Revue	Zepetella G, Joel SP, Ribiero MDC. Stability of morphine sulphate and diamorphine hydrochloride in Intrasite gel. Palliative Med 2005 ; 19: 131-136.

# Stabilis



## Morphine sulfate



### Stabilité des préparations

Icon	Icon	Icon	Icon	Icon	Icon	Icon	Icon	Icon	Icon
4 mg @ = Roxane Laboratories		Eau purifiée >> 10 ml	22°C		60				3426
2 mg @ = Morphine elixir (Roxane laboratories)		Eau distillée >> 1 ml	25°C		60				3866








































































### Bibliographie

	Type	Source
3426	Revue	Sauberan, Jason; Rossi, Steven; Kim, Jae H. Stability of Dilute Oral Morphine Solution for Neonatal Abstinence Syndrome. Journal of Addiction Medicine 2013 ; 7,2:113-115.
3866	Revue	Nahata M C. Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children. Int J Pharm Compound 2016 ; 30, 3 : 247-249.



# Dictionnaire

 Antalgique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 Non précisée
 Jour	 A l'abri de la lumière
 NaCl 0,9% ou glucose 5%	 Avec ou sans lumière
 Chlorure de sodium 0,9%	 NaCl 0,9% + bactériostatique
 Non précisé	 Polyvinyl chlorure
 Glucose 5%	 Lumière
 Heure	 Aucun
 Polypropylène	 Seringue polypropylène
 Elastomère en polyisoprène	 Non précisé
 Stabilité en mélange	 Solvant
 Molécule	 Polyolefine
 Synchroned®	 Facteur influençant la stabilité
 Provoque	 Dégradation
Nutrition parentérale (mélange ternaire)	 Précipitation
 Compatibilités	 Incompatibilité non précisée
 Incompatible	 Compatible
 Précipitation en 2 heures	 Instabilité chimique
 Turbidité immédiate	 Précipitation immédiate
<b>RL</b> Ringer lactate	 Instabilité de l'émulsion immédiate
Nutrition parentérale (mélange binaire)	 Perte de turbidité
 Turbidité à 24 heures	 Solvant spécifique
 Changement de couleur après 1 heure	 Instabilité de l'émulsion en 1 heure
 Précipitation en 1 heure	 Voie d'administration

 Intraveineuse	 Perfusion intraveineuse
 Perfusion continue	 Intramusculaire
 Sous cutanée	 Intrathécale
 Perfusion SC continue	 Bibliographie
 Forme dermique	 Stabilité des préparations
 Origine	 Excipient
 Flacon plastique	 Flacon injectable
 Poudre	 Solution buvable
 Liquide	 Seringue PP orale
 Dictionnaire	